- Total Pro Portfolios with MDCO:
- Franklin Biotechnology Discovery A - FBDIX
- show more
- 1
- Total Do-It-Yourself Portfolios with MDCO:
- FAVORSKI Portfolio 1
- Sundar Portfolio 1
- omero Portfolio 1
- fed4 10% below 200ma 6-20-07
- SUPRATRADE "BUY IT ALL TODAY" 0708071331(7.august)
- G Kernochan Portfolio 1
- August double bottom time to buy
- PART 3 JPMorgan 27th Annual Healthcare Conf 1/13/09..2nd Day Reporting Companies..Nymph Take
- miamirocksters Portfolio 1
- show more
- 18
- IBD Top 20 Outperformers
- eichigauger Portfolio 1
- growth funds
- Ram's
- youhow Portfolio 1
- PART 2 JPMorgan 26th Annual Healthcare Conf 1/7/08..1st Day Reporting Companies..Nymph Take
- Nurse Nymph looks for Medical Plays in this Sick Economy
- Barron's Research Reports 4-04-2009
- darrylb Portfolio 1
- News For Selected Stock
- Related stories on theStreet.com
- videos related to etf's
- No videos found
- blogs related to etf's
- No blogs found
Why I Love This Stock |
|
By:gnomeray |
Date:08 02 08 |
New monthly highs out of a year of consilidation |
|
Not yet rated
Rate now:
|
|
By:Pro |
Date:11 30 -1 |
Medicines Company (MDCO) was upgraded from Hold to Buy, Citigroup said. $29 price target. PCI volume should stabilize in 2008, and the company is also launching several new products in the coming quarters. |
|
Not yet rated
Rate now:
|
|
By:Pro |
Date:11 30 -1 |
Medicines (MDCO) was upgraded to Buy rating from Sell at UBS. Price target jumps to $23.50 from $17 and 2008 eps estimates lowered to $0.35 from $0.43. |
|
Not yet rated
Rate now:
|
|
By:supratrade |
Date:08 07 07 |
buy |
|
Not yet rated
Rate now:
|
|
By:Pro |
Date:11 30 -1 |
Upgraded by RBC from Underperform to Sector Perform |
|
Not yet rated
Rate now:
|
|
By:jesorensen |
Date:05 27 07 |
A mistake, based on Hilary Kramer's suggestion. With the patent renewal screwup and a weak pipeline there is more downside potential. Covered by options at 20 which will take a loss when assigned. |
|
Not yet rated
Rate now:
|
|
By:Pro |
Date:11 30 -1 |
Downgraded by RBC Capital Mkts from Outperform to Underperform |
|
Not yet rated
Rate now:
|
|
By:Pro |
Date:11 30 -1 |
Downgraded by UBS from Neutral to Reduce |
|
Not yet rated
Rate now:
|
|
Why I Hate This Stock |
|
| Comments not available |








